"Efesovir" (FS-1) for COVID-19, Phase 2
ConditionCovid19
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-59
SponsorScientific Center for Anti-infectious Drugs, Kazakhstan
About this trial
Study of the efficacy and safety of the new drug "Efesovir" in comparison with the drug "Remdesivir" in the treatment of patients hospitalized with COVID-19.
The hypothesis of clinical study is the clinical efficacy of new drug "Efesovir" is 10% to 30% higher than of "Remdesivir".
Eligibility criteria
Qualifiers
polymerase chain reaction (PCR) confirmed coronavirus infection (COVID-19) in hospitalized patients with severe risk factors in age from 18 years to 59 years, of both sexes, irrespective of national or ethnic origin
the duration of the COVID-19 disease is no more than 10 days
informed concent to participate in clinical trials
informed concent to to use reliable contraceptive methods while participating in a clinical trial
Disqualifiers
age less than 18 years old and over 59 years old
pregnancy or breastfeeding
hypersensitivity, allergy, intolerance to iodine, iodine-containing medicines
hypersensitivity to Remdesivir or its components
Trial design
Treatments tested in this trial
- Efesovir
Treatment groups
62 Participants
are divided into 2 treatment groupsLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Semey Medical University Status unavailable 071407, Semey, East Kazakhstan
Kazakhstan
KazakhstanSponsors and collaborators
Source ClinicalTrials.gov